Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune shot aims to halt oral cancer before it starts

NCT ID NCT06623110

Recruiting now Prevention Sponsor: Glenn J. Hanna Source: ClinicalTrials.gov ↗

First seen Apr 24, 2026 · Last updated May 02, 2026 · Updated 2 times

Summary

This study tests whether an injected immune therapy called RP2 can safely treat high-risk oral precancerous spots and prevent them from turning into oral cancer. About 25 adults with certain high-risk mouth conditions will receive the drug directly into the precancerous area. The goal is to see if the spots shrink or disappear, and how long people stay cancer-free.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK ORAL PRECANCEROUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

HIGH-RISK ORAL PRECANCEROUS DISEASE